ABSTRACT

The increase of eosinophil levels is a hallmark of type-2 inflammation. Blood eosinophil counts act as a convenient biomarker for asthma phenotyping and the selection of biologics, and they are even used as a prognostic factor for severe coronavirus disease 2019. However, the circulating eosinophil count does not always reflect tissue eosinophilia and vice versa. The mismatch of blood and tissue eosinophilia can be seen in various clinical settings. For example, blood eosinophil levels in patients with acute eosinophilic pneumonia are often within normal range despite the marked symptoms and increased number of eosinophils in bronchoalveolar lavage fluid. Histological studies using immunostaining for eosinophil granule proteins have revealed the extracellular deposition of granule proteins coincident with pathological conditions, even in the absence of a significant eosinophil infiltrate. The marked deposition of eosinophil granule proteins in tissue is often associated with cytolytic degranulation. Recent studies have indicated that extracellular trap cell death (ETosis) is a major mechanism of cytolysis. Cytolytic ETosis is a total cell degranulation in which cytoplasmic and nuclear contents, including DNA and histones that act as alarmins, are also released. In the present review, eosinophil-mediated inflammation in such mismatch conditions is discussed.

Keywords: Eosinophil granule proteins; Eosinophils; Extracellular traps

INTRODUCTION

Allergy, a hypersensitivity reaction initiated by specific immunologic mechanisms [1], is often associated with tissue eosinophilia [2]. In addition, eosinophil accumulation is also associated with malignancy, infection, and various homeostatic conditions. For example, eosinophils home into the uterus, which is regulated by the estrus cycle [3, 4]. Eosinophils in the blood can be readily counted. Although these cells form a minor (<5%) component of the circulating leukocyte population in the blood, larger numbers of tissue-dwelling eosinophils are present outside of the vasculature [5]. Nevertheless, the blood eosinophil count is an easy-to-access biomarker for various clinical applications. For asthma phenotyping and the
Conflict of interest
MF received grant support from GlaxoSmithKline Japan Research Grants 2018; PA has received research support and consultancy fees from and has been on advisory boards for AstraZeneca and GlaxoSmithKline; SU received honoraria for lectures from AstraZeneca and GlaxoSmithKline as well as grant support from AstraZeneca, Novartis, and Maruho. The rest of the authors have no conflicts of interest.

Author Contributions
Conceptualization: Shigeharu Ueki, Yui Miyabe, Mineyo Fukuchi, Yoshiki Kobayashi. Investigation: Yui Miyabe, Mineyo Fukuchi, Yoshiki Kobayashi. Project administration: Akiko Saga, Yuki Moritoki, Tomoo Saga, Shigeharu Ueki. Writing - original draft: Yui Miyabe, Mineyo Fukuchi, Yoshiki Kobayashi, Shigeharu Ueki. Writing - review & editing: Yui Miyabe, Mineyo Fukuchi, Praveen Akuthota, Akiko Saga, Yuki Moritoki, Tomoo Saga, Shigeharu Ueki.

Eosinophil-mediated inflammation

selection of biologics, the blood eosinophil count is the best-established biomarker [6]. In patients with severe chronic obstructive diseases, blood eosinophil counts are associated with the risk of exacerbations and the benefit of inhaled corticosteroid use [7]. A lower blood eosinophil count is also useful as a poor prognostic factor for severe coronavirus disease 2019 (COVID-19) [8, 9].

Eosinophils develop in the bone marrow and are released into blood circulation once they are maturated. Circulating eosinophils can subsequently transmigrate into the gastrointestinal tract, lungs, adipose tissue, thymus, spleen, lymph nodes, and mammary glands, where they exert various essential homeostatic functions [10, 11]. The life span of eosinophils is unclear, but it has been estimated to be less than 1 week under homeostatic conditions [12]. The tissue presence of eosinophils is determined by their recruitment, retention, and clearance [13]. Therefore, tissue eosinophilia can be caused by increased migration, prolonged survival, impaired phagocytic clearance, or decreased luminal entry [14].

The activation status of eosinophils is mainly tuned by receptors expressed on their cell surfaces. As a short-lived, nondividing cell, eosinophil “activation” has been recognized as the release of bioactive mediators into the extracellular milieu [15]. This is in contrast to lymphocytes, for which “activation” usually means proliferation and clonal expansion of antigen-specific lymphocytes [16]. The multifaceted role of eosinophils is evidenced by their range of cell densities and cell-derived mediators.

SECRETORY MECHANISMS OF EOSINOPHILS

Because eosinophils are a rich source of bioactive mediators, the simplified hypothesis is that the amount of eosinophil-derived inflammatory mediators in the microenvironment is the primary cause of eosinophilic inflammation. Eosinophils contain approximately 200 granules per cell [17]. These granules contain 4 major cationic (basic) proteins, that is, major basic protein (MBP), eosinophil-derived neurotoxin (EDN), eosinophil cationic protein (ECP), and eosinophil peroxidase (EPO), which play important roles in eosinophil-mediated inflammation [18]. Granule-stored cytokines in human eosinophils are released by 3 secretory processes: classical exocytosis, piecemeal degranulation, and cytolysis/extracellular trap cell death (ETosis) [5, 19].

Classical exocytosis is a granule secretory system in which intracellular granules fuse with the plasma membrane and release their entire contents extracellularly via a secretory pore. This mechanism is not usually observed in vivo. In compound exocytosis, granules fuse to each other, forming large channels within the cytoplasm, and the cells then secrete the entire intragranular contents of multiple granules [18].

Piecemeal degranulation is thought to be the main degranulation process used by eosinophils. In piecemeal degranulation, the granule contents are selectively mobilized into small round vesicles and tubular structures termed eosinophil sombrero vesicles. The tubular eosinophil sombrero vesicles express cytokine receptor chains that are bound by cytokine ligands, such as interleukin (IL)-4 [5]. These vesicles become fused with the plasma membrane and release their granule-derived contents into extracellular spaces [20, 21]. Ultrastructure of exocytosis and piecemeal degranulation show an emptying of the secretory granules or lumen areas in the core of intact eosinophils [18].
Cytolysis or ETosis is a recently recognized type of programmed cell death that is characterized by the dissolution of nuclear and plasma membranes and release of chromatin fiber called an extracellular trap [22-24]. In eosinophils, ETosis-derived cell-free extracellular granules express functional receptors on their membranes [18, 19, 25, 26]. Upon activation by ligand stimulation, the granules release their contents, which include EDN [27, 28]. Eosinophil ETosis (EETosis) is considered to contribute to the sterilization and trapping of pathogens by extracellular traps, granule proteins, and nuclear-derived components, all of which have cytotoxicity [29, 30].

**BIOACTIVE MEDIATORS OF EOSINOPHILS**

The functions of the major mediators derived from human eosinophils are summarized in Table 1. MBP is localized in the core of specific granules, while EDN, ECP, and EPO are localized in the matrix of specific granules [31-33]. Although all 4 of these granule proteins have toxicity for helminth parasites [34], each has various biological activities in addition to its antimicrobial activity. MBP-2 and EPO are distributed only in eosinophils [35, 36], whereas the other granule proteins are found in additional cells and tissues [37-39].

| Table 1. Eosinophil-derived mediators |
|--------------------------------------|

| Eosinophil | Mediators | Cell distribution | Functions | Selected references |
|------------|-----------|------------------|-----------|---------------------|
| MBP1/2     | Granule core | Toxic to cells and tissues | Gleich GJ, et al. J Immunol 1979;123:2925–7. [46] |
|            | Granule core | Toxic to helminth parasites | Hamann KJ, et al. J Immunol 1990;144:3166–73. [34] |
|            | Granule core | Toxic to bacteria | Butterworth AE, et al. J Immunol 1979;122:221–9. [162] |
|            | Granule core | Disrupts the lipid bilayer membrane | Lehrer RI, et al. J Immunol 1989;142:4428–34. [41] |
|            | Granule core | Inhibits the Muscaline 2 receptor | Gleich GJ, et al. Annu Rev Med 1993;44:85–101. [163] |
|            | Granule core | Induces mediator release from basophils and mast cells | Jacoby DB, et al. J Clin Invest 1993;91:1314–8. [49] |
|            | Granule core | Induces IL-8 production from eosinophils | O’Donnell MC, et al. J Exp Med 1983;157:1981–91. [42] |
|            | Granule core | Induces detachment of tracheal epithelial cells | Fujisawa D, et al. J Allergy Clin Immunol 2014;134:622–33.e9. [43] |
|            | Granule core | Induces cessation of ciliary activity | Zheutlin LM, et al. Int Arch Allergy Appl Immunol 1985;77:216–7. [164] |
|            | Granule core | Induces platelet activation | Kita H, et al. J Immunol 1995;154:4749–58. [45] |
|            | Granule core | Induces amyloid deposition | Hamill AT, et al. Am Rev Respir Dis 1987;135:848–53. [47] |
|            | Granule core | Toxic to helminth parasites | Rohrbach MS, et al. J Exp Med 1990;172:1271–4. [40] |
|            | Granule core | Has RNase2 activity | Soragni A, et al. Mol Cell 2015;77:1071–21. [165] |
|            | Granule core | Induces the Gordon phenomenon | Hamann KJ, et al. J Immunol 1990;144:3166–73. [34] |
|            | Granule core | Induces dendritic cell activation | Slifman NR, et al. J Immunol 1986;137:2913–7. [166] |
|            | Granule core | Induces MMP9 expression and apoptosis in keratinocytes | Fredens K, et al. J Allergy Clin Immunol 1982;70:361–6. [167] |
|            | Granule core | Induces MMP9 expression and apoptosis in keratinocytes | Yang D, et al. J Exp Med 2008;205:79–90. [57] |
|            | Granule core | Induces the Gordon phenomenon | Amber KT, et al. Exp Dermatol 2018;27:1322–7. [67] |
|            | Granule core | Has RNase3 activity | Gullberg U, et al. Biochem Biophys Res Commun 1986;139:1239–42. [61] |
|            | Granule core | Induces the Gordon phenomenon | Slifman NR, et al. J Immunol 1986;137:2913–7. [166] |
|            | Granule matrix | Toxic to helminth parasites | Fredens K, et al. J Allergy Clin Immunol 1989;70:361–6. [167] |
|            | Granule matrix | Has RNase3 activity | McLaren DJ, et al. Parasite Immunol 1981;3:359–73. [62] |
|            | Granule matrix | Cytotoxic | Hamann KJ, et al. J Parasitol 1987;73:523–9. [54] |
|            | Granule matrix | Toxic to bacteria | Rosenberg HF and Dyer KD. J Biol Chem 1995;270:7876–81. [168] |
|            | Granule matrix | Induces amyloid-like aggregation | Lehrer RI, et al. J Immunol 1989;142:4428–34. [41] |
|            | Granule matrix | Induces mediator release from basophils and mast cells | Torrent M, et al. Plos Pathogens 2012;8:e1003005. [56] |
|            | Granule matrix | Inhibits TNF-α production by human macrophages | Zheutlin LM, et al. Int Arch Allergy Appl Immunol 1985;77:216–7. [164] |
|            | Granule matrix | Enhances factor XII-dependent reactions | Dahl R and Venge P. Thromb Res 1979;14:599–608. [65] |
|            | Granule matrix | Enhances factor XII-dependent reactions | Venge P, et al. Thromb Res 1979;14:641–9. [64] |

(continued to the next page)
| Eosinophil | Mediators | Cell distribution | Functions | Selected references |
|-----------|-----------|-------------------|-----------|---------------------|
| EPO       | Granule matrix | Toxic to helminth parasites | Hamann KJ, et al. J Immunol 1990;144:3166–73. [34] |
|           |           | Toxic to bacteria | Migler R, et al. Blood 1978;51:445–56. [75] |
|           |           | Toxic to tumor cells | Wang JG, et al. Blood 2006;107:558–65. [77] |
|           |           | Induces tissue factor and thrombosis | Wang JG, et al. Blood 2006;107:558–65. [77] |
|           |           | Binds to the surface of microorganisms and enhances phagocytosis | Ramsey PG, et al. J Immunol 1982;128:415–20. [78] |
|           |           | Mediates mucus plugging of the airways | Fujisawa D, et al. J Allergy Clin Immunol 2014;134:622–33.e9 [43]. |
|           |           | Inactivates leukotrienes | Henderson WR, et al. J Immunol 1982;128:2609–13. [87] |
|           |           | Induces histamine release from mast cells | Henderson WR, et al. J Exp Med 1980;152:265–79. [80] |
| Galectin-10 | Peripheral cytoplasm | Forms Charcot-Leyden crystals | Ueki S, et al. Blood 2013;121:1837–8. [84] |
|           |           | Promotes allergic inflammation | Persson EK, et al. Science 2019;364:4295. [76] |
|           |           | Regulates the proliferative capacity and suppressive function of CD25+ Treg cells | Garcia-Romo GS, et al. Sci Transl Med 2011;3:73ra20. [104] |
|           |           | Involved in the secretory response via lysophospholipase activity | Bosmann M, et al. Faseb J 2013;27:5010–21. [173] |
|           |           | Induces granulogenesis and vesicular transport of granule proteins | Kubach J, et al. Blood 2007;110:1550–8. [169] |

**Nonspecific for eosinophil**

| Histones | Nucleus | Promotes apoptosis | Barrero CA, et al. Am J Respir Crit Care Med 2013;188:673–83. [91] |
|----------|---------|--------------------|--------------------------|
|          |         | Stimulates neurogenesis | Hirsch JG. J Exp Med 1958;108:925–44. [90] |
|          |         | Regulates macrophage migration and endocytosis | Mishra B, et al. J Neurosci 2010;30:12400–13. [71] |
|          |         | Regulates neutrophil migration | Brix K, et al. J Clin Invest 1998;102:283–93. [71] |
|          |         | Cytotoxic to endothelial cells | Xu J, et al. Nat Med 2009;15:1318–21. (in mice) [72] |
|          |         | Induces NLRP3 Inflammasome activation | Bosmann M, et al. Facseb J 2013;27:5010–21. [73] |
|          |         | Toxic to bacteria | Allam R, et al. J Am Soc Nephrol 2012;23:1375–88. [74] |
|          |         | Stimulates TLR signaling pathways | Allam R, et al. Eur J Immunol 2013;43:3336–42. [96] |
|          |         | Promotes thrombin generation | Zhang J, et al. J Immunol 2006;177:101–12. [97] |
|          |         | Promotes platelet aggregation | Fuchs TA, et al. Blood 2011;118:3708–14. (in mice) [98] |
| dsDNA    | Nucleus | Contributes to microbial pathogen containment | Carestia A, et al. J Allergy 2013;10:1035–45. [100] |
|          |         | Stimulates autoimmune responses | Kaplan MJ and Radic M. J Immunol 2012;188:2689–95. [89] |
|          |         | Induces vascular damage | Garcia-Romo GS, et al. Sci Transl Med 2011;3:73ra20. [104] |
|          |         | Promotes thrombosis | Hakkim A, et al. Proc Natl Acad Sci USA 2010;107:3813–8. [175] |

**Major basic protein**

There are 2 types of MBP: MBP-1 and MBP-2. MBP-1 is more potent and more widespread compared with its homologue MBP-2, which is only present in eosinophils [35]. MBP is rich in arginine and has strong basicity [40]. It mediates cytotoxicity for bacteria by increasing the permeability of cell membranes [41]. Both MBP and EPO induce histamine release from basophils and mast cells, and histamine release in mast cells occurs through the Mas-related pathway.

**Table 1. (Continued) Eosinophil-derived mediators**

| MBP1/2, major basic protein 1/2; IL-8, interleukin-8; EDN, eosinophil-derived neurotoxin; MMP9, matrix metalloproteinase 9; ECP, eosinophil cationic protein; TNF, tumor necrosis factor; EPO, eosinophil peroxidase; TLR, Toll-like receptor; dsDNA, double-stranded DNA. |
Eosinophil-mediated inflammation

Eosinophil-derived neurotoxin

The RNase superfamily member EDN, encoded in humans by the gene RNASE2, is the second-most abundant protein in the human eosinophil proteome out of the 7,086 proteins identified by proteomics of peripheral blood eosinophils [50]. EDN can be isolated not only from eosinophils but also from neutrophils as well as the liver, spleen, kidney, and urine [38, 51-53]. In neutrophils, EDN is present in the neutrophilic granules, as demonstrated by immunoelectron microscopy [38]. EDN has limited toxicity for helminth parasites compared with MBP and ECP [34, 54], but this protein is active against RNA viruses. Additionally, EDN is 100-fold more ribonucleolytically active compared with ECP [55]. Intrathecal injection of EDN or ECP into rabbits causes the death of cerebellar Purkinje fibers, which is known as the Gordon phenomenon [56]. A recent report has shown that EDN can act as an alarmin, is involved in the activation of dendritic cells through the TLR2–MyD88 signaling pathway, and activates the type-2 immune response [57].

Eosinophil cationic protein

ECP, encoded in humans by the gene RNASE3, also belongs to the RNase superfamily. Compared with EDN, ECP is more cationic and more toxic to bacteria [58]. ECP can destabilize bacterial lipid bilayers and neutralize bacterial lipopolysaccharide, which contribute to the toxicity of ECP to bacteria [59, 60]. However, ECP has 125 times lower RNase activity compared with EDN [61]. Regarding the toxicity of ECP to Schistosoma mansoni, electron microscopy observation revealed that in ECP-treated S. mansoni, blebs were formed on the surface of the parasite and the surface of the parasite was ruptured [62]. The toxicity to helminth parasites of ECP is equivalent to the effect of MBP, but the effect of ECP is slower than that of MBP [54]. Like MBP, ECP mediates histamine release in basophils and mast cells [63]. ECP increases the activation of kalikrein, enhances factor XII, and shortens the blood coagulation time [64]. ECP is also involved in fibrinolysis via plasminogen enhancement [65]. Additionally, ECP inhibits microbial activity by forming amyloid-like aggregates on bacterial surfaces [66]. In a recent report, ECP and EDN both induced the expression of matrix metalloproteinase 9 in keratinocytes and triggered keratinocyte apoptosis, which suggests their potential as therapeutic targets for bullous pemphigoid [67].

Eosinophil peroxidase

EPO is highly cationic, heme-containing oxidoreductase that is similar to myeloperoxidase (MPO) in neutrophils [68]. Although EPO and MPO have 68.3% of the same amino acids [69], there are some differences in their functions; for example, EPO binds to antineutrophil cytoplasmic antibodies and is involved in renal fibrosis [70, 71]. EPO is taken up by
neutrophils, basophils, and mast cells, and EPO has a higher affinity for neutrophils compared with MPO [72, 73]. By acting as an oxidoreductase, halides are coactivated with reactive oxygen species to produce hypochlorous acid, which is highly toxic to helminth parasites and bacteria [74, 75] as well as toxic to tumor cells [76]. Hypothiocyanous acid (HOSCN) is produced by the oxidation of EPO and induces tissue factor activation, which suggests its involvement in thrombosis. HOSCN also activates the proinflammatory p65/p50 nuclear factor-κB pathway [77]. EPO binds to the surface of microorganisms, thereby facilitating macrophage phagocytosis even in microorganisms that are resistant to macrophage destruction [78]. EPO is associated with mucus plugging of the airways in asthma [79]. Similar to MBP and ECP, EPO induces mast cell degranulation [80]. EPO also inactivates leukotrienes B4, C4, and D4 [81].

Galectin-10 (Charcot-Leyden crystal protein)
Galectin-10 is a cytoplasmic protein that belongs to S-lectin family and the fifth most abundant protein in eosinophils [50]. It was originally recognized as Charcot-Leyden crystal (CLC) protein and later named galectin-10 because of its carbohydrate-binding domain, which is similar to those of other galectin family members. Galectin-10 is expressed predominantly on eosinophils but is also present on macrophages, basophils, and CD4+CD25+ regulatory T cells [82]. In unstimulated eosinophils, galectin-10 is localized in the peripheral cytoplasm [83]. During the process of EETosis, galectin-10 can redistribute in the cytoplasm and form CLCs intracellularly [84]. EETosis-mediated plasma membrane disintegration causes the extracellular release of galectin-10, resulting in the extracellular formation of CLCs [84]. Recent reports indicate that CLCs promote type-2 immunity [85] and also neutrophilic inflammation [86]. The full function of galectin-10 is still unclear, but reports suggest that this protein regulates the dynamic palmitoylation cycle [87] and is involved in vesicular transport systems and granulogenesis [88].

Histones and double-stranded DNA
EETosis releases eosinophil extracellular traps, which are composed mainly of histones and double-stranded DNA, that is, chromatin fiber. Eosinophil extracellular traps are effective at trapping microbial pathogens because of their net-like structure [89]. A proteome analysis of human eosinophils indicated that histones ranked 3rd, 4th, 6th, and 15th in abundance among the top 15 proteins [50]. The cytotoxic effects to bacteria of histones have been known for more than 50 years [90]. Histones promote cell apoptosis [91, 92] and are involved in inflammation by stimulating Toll-like receptor signaling pathways [93-95] or NLRP3 inflammasomes [96, 97]. Histones have also been recognized as inducers of the blood coagulation system [98-101]. Extracellular double-stranded DNA is known to cause vascular damage [102, 103] and thrombosis, and it can stimulate autoimmune responses, such as systemic lupus erythematosus [104-106].

Other cytokines and lipid mediators
Eosinophils are a rich source of cysteinyl leukotrienes (cysLTs). Leukotriene C4 and its metabolites, leukotriene D4 and leukotriene E4, have varied roles in mediating eosinophilic disorders, including host defense against parasites and allergic inflammation. CysLTs can activate eosinophils in an autocrine manner (they prolong survival), and induce reactive oxygen species production and EDN release from eosinophils [107, 108]. CysLTs are also involved in eosinophil differentiation and maturation in combination with IL-5 [109]. Additionally, extracellular eosinophil granules can release ECP in response to cysLT stimulation via cysLT receptors expressed on the granule membrane [110].
Eosinophils store a wide array of cytokines, chemokines, and growth factors, including IL-4 [111, 112], granulocyte macrophage colony-stimulating factor (GM-CSF) [113-115], and TGF-β [116-118]. IL-4 induces eosinophil migration into tissues via the expression of adhesion molecule vascular cell adhesion molecule-1 on endothelial cells [119]. Various stimuli, including calcium ionophore [113, 114] and fibronectin [115], can induce GM-CSF production in eosinophils. GM-CSF is involved in the type-2 response in allergic airway inflammation through activating dendritic cells and enhancing eosinophil survival in an autocrine manner [120, 121].

PERIPHERAL VERSUS TISSUE EOSINOPHILIA: LESSONS FROM ACUTE EOSINOPHILIC PNEUMONIA

Peripheral blood eosinophilia can assist in the diagnosis of eosinophilic inflammatory diseases, including eosinophilic pneumonia. Unlike the diagnostic criteria for chronic eosinophilic pneumonia with peripheral blood eosinophilia, the diagnostic criteria for acute eosinophilic pneumonia (AEP) do not require peripheral blood eosinophilia [122]. AEP is caused mainly by inhalational exposure, such as cigarette smoke, including electronic cigarettes or heated tobacco [123], and develops acutely along with respiratory failure. Peripheral blood eosinophilia may be absent at the onset of AEP, especially in smoking-related AEP [124].

We experienced a case in which bacterial pneumonia was suspected because of the patient’s neutrophilia, and the results of a bronchoalveolar lavage led to the diagnosis of AEP. A 21-year-old woman had fever and dyspnea 1 week after smoking initiation. Upon hospitalization, she was febrile (39.6°C) and tachypneic with a reduced peripheral oxygen saturation (91%). Her arterial blood gases under room air were: pH, 7.44; PaO₂, 55 mmHg; and PaCO₂, 30 mmHg. Her chest x-ray showed bilateral ground glass attenuations mixed with consolidations and a slight pleural effusion.

The laboratory test revealed a white blood cell count of 23,400 cells/µL with neutrophilia (95.8%, 22,417 cells/µL). Her serum C-reactive protein level was 8.2 mg/dL (normal, <0.3 mg/dL), IL-5 level was 1,012 pg/mL (normal, <3.9 pg/mL), and ECP level was 68.9 µg/L (normal, <14.9 µg/L), and her peripheral blood eosinophil count was only 94 cells/µL. Conversely, a marked elevation of eosinophils was observed in her bronchoalveolar lavage fluid (71% eosinophils in the differential cell count), leading to the diagnosis of AEP. A single administration of methylprednisolone (40 mg) and the cessation of cigarette smoking dramatically improved the symptoms of AEP. Notably, in parallel with the patient’s improvement of bilateral pulmonary infiltration, her peripheral eosinophil counts reached up to 1,250 cells/µL on day 9 (6 days after methylprednisolone administration) (Fig. 1A, B).

Before or during eosinophil movement, a cellular shape change related to migration is necessary [2]. We conducted an ex vivo eosinophil shape change assay by using flow cytometric measurement of autofluorescence/forward scatter on cells stimulated with cigarette smoke extract [125]. A clear shape change was induced in the patient’s eosinophils at the onset, and such changes were not reproduced in cells taken from the patient after the resolution of AEP or in eosinophils from a normal donor (Fig. 1C). Thus, it can be speculated that eosinophils have the potential to accumulate in the lung at the onset of AEP.

IL-5 plays a critical role in an eosinophilopoiesis, chemokinesis/chemotaxis, integrin activation, and survival prolongation via apoptosis inhibition [6]. In our case, the initially
elevated serum IL-5 level was associated with AEP disease severity, despite the peripheral blood eosinophil counts being in the normal range. Interestingly, serum IL-5 levels have been shown to inversely correlate with peripheral blood eosinophil counts in patients in the initial state of AEP. This is likely caused by the rapid migration of blood eosinophils to the lungs, as illustrated in Fig. 2A. Notably, the pathological condition of asthma was recreated in lung-specific IL-5 transgenic mice but not in “systemic” IL-5 transgenic mice. Tissue-specific overproduction of IL-5 might play an important role in the pathogenesis of AEP by recruiting eosinophils from the peripheral blood into the lungs.

In patients with atopic asthma, sputum eosinophil counts and serum IL-5 levels increase after allergen inhalation, whereas blood eosinophil counts decrease for 12 hours. The intravascular residence time of radiolabeled eosinophils in healthy volunteers is approximately 25 hours, although it can be 1.5 hours in a patient with tissue eosinophilic inflammation. Accumulated eosinophils might directly induce eosinophilia through the production of eosinophil chemoattractants, such as leukotriene B4 and C-C chemokine ligand 4. These data suggest that a dynamic shift of circulating eosinophils into the tissue can occur.

Transient blood eosinophilia after systemic corticosteroid administration is another interesting feature of the present case. This phenomenon has been reported previously;
serum IL-5 rapidly falls into the normal range within 10 days [126], whereas peripheral blood eosinophil counts increase with radiographic and clinical resolution during the following days [126, 133, 134].

Corticosteroids have various potent anti-inflammatory effects on allergic inflammation. They can induce eosinophil apoptosis directly as well as can indirectly, by inhibiting the production of survival factors including IL-5 [135, 136]. In addition, corticosteroids enhance the phagocytic capacity of macrophages and airway epithelial cells [136, 137]. Apoptotic eosinophils are intact when they are recognized and engulfed by phagocytes, so they do not induce inflammation [138]. As illustrated in Fig. 2B, after the treatment of AEP with a systemic steroid, eosinophilic lung inflammation is resolved, likely through the clearance of apoptotic eosinophils in the lungs. It is also conceivable that the decreased recruitment of blood eosinophils into the lung might result in the retention of eosinophils in circulation, leading to a transient blood eosinophilia.

The mismatch of circulating and tissue eosinophilia is not limited to AEP. For instance, we have also experienced a case in which a patient with GM-CSF-producing lung cancer showed no clinical manifestations or evidence of tissue eosinophilia despite having marked blood eosinophilia (>30,000 cells/µL) [139]. Dupilumab, an anti-IL-4Ra antibody that blocks both IL-4 and IL-13 signaling, can trigger eosinophilia without the presentation of clinical signs of organ involvement owing to eosinophil infiltration [140]. The mechanisms underlying dupilumab-induced eosinophilia remain unknown, but it has been hypothesized that dupilumab blocks the migration of eosinophils into tissue without blocking eosinophil
production in the bone marrow [141]. Hypereosinophilia is defined by a peripheral blood absolute eosinophil count of greater than 1,500 cells/µL that may not be associated with tissue damage [142]. In addition to patients with hypereosinophilic syndrome, who typically require treatment to prevent disease progression, there are patients with unexplained persistent asymptomatic hypereosinophilia. Additionally, clinical manifestation related to eosinophilic inflammation is uncommon in patients with familial eosinophilia [143]. Thus, the circulating eosinophil count does not always reflect tissue eosinophilia and vice versa.

“EOSINOPHILIC” TISSUE IN THE ABSENCE OF EOSINOPHILS

Tissue hypereosinophilia can be defined as tissue with a percentage of eosinophils that exceeds 20% of all nucleated cells in the bone marrow or tissue infiltration that is deemed extensive by a pathologist [11, 144]. However, historical studies with immunostaining for eosinophil granule proteins have revealed the extracellular deposition of granule proteins coincident with pathological conditions, even in the absence of a significant eosinophil infiltrate. Frigas ans Gleich [145] described the lung tissue specimens from autopsy cases who died of asthma as follows: “some eosinophils were intact, others were partially degranulated and surrounded by their extruded granules, and others were totally disrupted and unrecognizable by hematoxylin and eosin stain.” In atopic patients challenged with an intradermal injection of allergen, MBP and EDN were extensively deposited throughout the dermis in the late-phase reaction [146]. Tissue deposition of granule protein in the absence of eosinophil accumulation has also been reported by Gleich et al. in cases of Hodgkin’s disease [147], parasite infection [148, 149], chronic urticaria [150], atopic dermatitis [151], and endomyocardial disease [152]. Several studies have indicated that granule protein deposition, rather than intact eosinophils, is associated with tissue remodeling [153, 154]. Given the toxicity of eosinophil granule proteins, histologic evidence of extracellular granule protein deposition in the tissue might be a more appropriate marker for inflammation than tissue eosinophilia.

Our group has studied hundreds of tissues from patients with allergic or eosinophilic diseases [26, 29, 83, 84, 155-160]. In our tissue immunostaining experience, like Gleich et al., we have observed that the extracellular deposition of MBP is not disease-specific, but it is closely associated with tissue damage and the presence of eosinophil cytolsis. Fig. 3 shows a typical example: surgically obtained nasal polyps from a case of chronic rhinosinusitis with nasal polyps (eosinophilic chronic rhinosinusitis). Hematoxylin and eosin staining revealed that the accumulated eosinophils were cytolytic, showing extracellular cell-free granules and chromatolysis and/or a loss of nuclear envelope. Immunostaining indicated a massive deposition of extracellular MBP that is consistent with the presence of cytolytic eosinophils. These cytolytic eosinophils were ultrastructurally identical to EETosis induced by various stimuli in vitro [26, 83].

Apoptosis facilitates the ingestion of intact eosinophils without a disgorgement of their toxic contents, and this process is necessary for the normal resolution of inflammation [138]. Impaired phagocytic clearance (efferocytosis) of lytic eosinophils is a critical feature of persistent inflammation. Notably, efferocytosis by phagocytic cells might not be applicable for EToxic cells, because of their rapid cell death process (0.5–3 hours) and lack of find-me signal exposure before cell lysis [25, 26]. Therefore, eosinophil cell fate within tissues might have completely different consequences (Fig. 4).
CONCLUSIONS

The presence of eosinophils is an important feature of type-2 inflammation, but clinical observations have indicated that eosinophil-mediated inflammation is not always coincident with an increase in eosinophil counts. As shown in the case of AEP, there are various examples of mismatch between the circulating eosinophil count and clinical manifestation. As stated above, considerable evidence has indicated that the marked deposition of eosinophil granule proteins in tissue is associated with tissue damage and remodeling. The most important feature of eosinophils as end-stage effector cells is their activation to release eosinophil granule proteins.
toxic cellular contents. In this context, eosinophils can be innocent bystanders without the secretion of their bioactive mediators.

EETosis is now considered to be a major mechanism of cytolytic degranulation. This process is not only a total cell degranulation but also a release of cytoplasmic and nuclear contents, including DNA and histones that act as alarmins. Although the maintenance of tissue eosinophils is tightly related to the ability of the cell and the microenvironment to maintain an appropriate balance between survival and active cell death pathways, it is not yet fully understood. Further study will lead to a better understanding of eosinophil-mediated inflammation and its treatment.

ACKNOWLEDGEMENTS

The authors are grateful to Noriko Tan for technical assistance and Satomi Misawa for outstanding assistance in drawing the figures. They also thank Katie Oakley, PhD, from Edanz Group (https://en-author-services.edanz.com/ac) for editing a draft of this manuscript. For all clinical samples, written informed consent was obtained from all participants in accordance with the Declaration of Helsinki and institutional review board-approved protocols.

REFERENCES

1. Johansson SG, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF, Motala C, Ortega Martell JA, Platts-Mills TA, Ring J, Thien F, Van Cauwenberge P, Williams HC. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol 2004;113:832-6.

2. Ueki S, Kihara J, Kato H, Ito W, Takeda M, Kobayashi Y, Kayaba H, Chihara J. Soluble vascular cell adhesion molecule-1 induces human eosinophil migration. Allergy 2009;64:718-24.

3. Gouon-Evans V, Pollard JW. Eotaxin is required for eosinophil homing into the stroma of the pubertal and cycling uterus. Endocrinology 2001;142:4515-21.

4. Tamaki M, Konno Y, Kobayashi Y, Takeda M, Itoha M, Moritoki Y, Oyamada H, Kayaba H, Chihara J, Ueki S. Expression and functional roles of G-protein-coupled estrogen receptor (GPER) in human eosinophils. Immunol Lett 2014;160:72-8.

5. Weller PF, Spencer LA. Functions of tissue-resident eosinophils. Nat Rev Immunol 2017;17:746-60.

6. Nagase H, Ueki S, Fujieda S. The roles of IL-5 and anti-IL-5 treatment in eosinophilic diseases: Asthma, eosinophilic granulomatosis with polyangiitis, and eosinophilic chronic rhinosinusitis. Allergol Int 2020;69:178-86.

7. Hambleton K, Pavord ID. What can we learn from blood granulocyte patterns in patients with asthma? Eur Respir J 2016;48:976-8.

8. Lindsley AW, Schwartz JT, Rothenberg ME. Eosinophil responses during COVID-19 infections and coronavirus vaccination. J Allergy Clin Immunol 2020;146:1-7.

9. Ferstroaaru D, Hudes G, Jerschow E, Jariwala S, Karagic M, de Vos G, Rosenstreich D, Ramesh M. Eosinophilia in asthma patients is protective against severe COVID-19 illness. J Allergy Clin Immunol Pract 2021;9:1152-62.e3.
10. Marichal T, Mesnil C, Bureau F. Homeostatic eosinophils: characteristics and functions. Front Med (Lausanne) 2017;4:101.

11. Valent P, Klion AD, Horny HP, Roufosse E, Gotlib J, Weller PF, Hellmann A, Metzgeroth G, Leiferman KM, Arock M, Butterfield JH, Sperr WR, Sotlar K, Vandenberghe P, Haferlach T, Simon HU, Reiter A, Gleich GJ. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol 2012;130:607-42.e9.

12. Klion AD, Ackerman SJ, Bochner BS. Contributions of eosinophils to human health and disease. Annu Rev Pathol 2020;15:179-209.

13. Asano K, Ueki S, Tamari M, Imoto Y, Fujieda S, Taniguchi M. Adult-onset eosinophilic airway diseases. Allergy 2020;75:3087-99.

14. Uller L, Persson CG, Källström L, Erjefält JS. Lung tissue eosinophils may be cleared through luminal entry rather than apoptosis: effects of steroid treatment. Am J Respir Crit Care Med 2001;164(10 Pt 1):1948-56.

15. Venge P, Håkansson L, Peterson CG. Eosinophil activation in allergic disease. Int Arch Allergy Appl Immunol 1987;82:333-7.

16. Heinz S, Marchingo JM, Horton MB, Hodgkin PD. The regulation of lymphocyte activation and proliferation. Curr Opin Immunol 2018;51:32-8.

17. Ueki S, Ohta N, Takeda M, Konno Y, Hirokawa M. Eosinophilic otitis media: the aftermath of eosinophil extracellular trap cell death. Curr Allergy Asthma Rep 2017;17:33.

18. Melo RCN, Weller PF. Contemporary understanding of the secretory granules in human eosinophils. J Leukoc Biol 2018;104:85-93.

19. Spencer LA, Bonjour K, Melo RC, Weller PF. Eosinophil secretion of granule-derived cytokines. Front Immunol 2014;5:496.

20. Melo RC, Spencer LA, Perez SA, Ghiran I, Dvorak AM, Weller PF. Human eosinophils secrete preformed, granule-stored interleukin-4 through distinct vesicular compartments. Traffic 2005;6:1047-57.

21. Melo RC, Weller PF. Piecemeal degranulation in human eosinophils: a distinct secretion mechanism underlying inflammatory responses. Histol Histopathol 2010;25:1341-54.

22. Fuchs TA, Abed U, Goosmann C, Hurwitz R, Schulze I, Wahn V, Weinrauch Y, Brinkmann V, Zychlinsky A. Novel cell death program leads to neutrophil extracellular traps. J Cell Biol 2007;176:231-41.

23. Wartha F, Henriques-Normark B. ETosis: a novel cell death pathway. Sci Signal 2008;1:pe25.

24. Guimarães-Costa AB, Nascimento MT, Wardini AB, Pinto-da-Silva LH, Saraiva EM. ETosis: a microbicidal mechanism beyond cell death. J Parasitol Res 2012;2012:929743.

25. Ueki S, Tokunaga T, Fujieda S, Honda K, Hirokawa M, Spencer LA, Weller PF. Eosinophil ETosis and DNA traps: a new look at eosinophilic inflammation. Curr Allergy Asthma Rep 2016;16:54.

26. Ueki S, Melo RC, Ghiran I, Spencer LA, Dvorak AM, Weller PF. Eosinophil extracellular DNA trap cell death mediates lytic release of free secretion-competent eosinophil granules in humans. Blood 2013;121:2074-83.

27. Shamri R, Melo RC, Young KM, Bivas-Benita M, Xenakis JJ, Spencer LA, Weller PF. CCL11 elicits secretion of RNases from mouse eosinophils and their cell-free granules. FASEB J 2012;26:2084-93.

28. Neves JS, Perez SA, Spencer LA, Melo RC, Reynolds L, Ghiran I, Mahmudi-Azer S, Odemuyiwa SO, Dvorak AM, Moqbel R, Weller PF. Eosinophil granules function extracellularly as receptor-mediated secretory organelles. Proc Natl Acad Sci U S A 2008;105:18478-83.
29. Ueki S, Konno Y, Takeda M, Moritoki Y, Hirokawa M, Matsuwaki Y, Honda K, Ohta N, Yamamoto S, Takagi Y, Wada A, WELLER PF. Eosinophil extracellular trap cell death-derived DNA traps: Their presence in secretions and functional attributes. J Allergy Clin Immunol 2016;137:258-67.

30. Muniz VS, Silva JC, Braga YAV, Melo RCN, Ueki S, Takeda M, Bebisawa A, Assan K, Figueiredo RT, Neves IS. Eosinophils release extracellular DNA traps in response to Aspergillus fumigatus. J Allergy Clin Immunol 2018;141:571-85.e7.

31. Lewis DM, Lewis JC, Loegering DA, Gleich GJ. Localization of the guinea pig eosinophil major basic protein to the core of the granule. J Cell Biol 1978;77:702-43.

32. Ackerman SJ, Loegering DA, Venge P, Olsson I, Harley JB, Fauci AS, Gleich GJ. Distinctive cationic proteins of the human eosinophil granule: major basic protein, eosinophil cationic protein, and eosinophil-derived neurotoxin. J Immunol 1983;131:2977-82.

33. Lewis DM, Loegering DA, Gleich GJ. Isolation and partial characterization of a major basic protein from rat eosinophil granules. Proc Soc Exp Biol Med 1976;152:512-5.

34. Hamann KJ, Gleich GJ, Checkel JL, Loegering DA, McCall JW, Barker RL. In vitro killing of microfilariae of Brugia pahangi and Brugia malayi by eosinophil granule proteins. J Immunol 1990;144:3166-73.

35. Plager DA, Loegering DA, Checkel JL, Tang J, Kephart GM, Caffes PL, Adolphson CR, Ohnuki LE, Gleich GJ. Major basic protein homolog (MBP2): a specific human eosinophil marker. J Immunol 2006;177:7340-5.

36. Nair P, Ochukur SI, Protheroe C, Radford K, Efthimiadis A, Lee NA, Lee JJ. Eosinophil peroxidase in sputum represents a unique biomarker of airway eosinophilia. Allergy 2013;68:1177-84.

37. Nakajima T, Matsumoto K, Suto H, Tanaka K, Ebisawa M, Tomita H, Yuki K, Katsunuma T, Akasawa A, Hashida R, Sugita Y, Ogawa H, Ra C, Saito H. Gene expression screening of human mast cells and eosinophils using high-density oligonucleotide probe arrays: abundant expression of major basic protein in mast cells. Blood 2001;98:1127-34.

38. Sur S, Glitz DG, Kita H, Kujawa SM, Peterson EA, Weiler DA, Kephart GM, Wagner JM, George TJ, Gleich GJ, Leiferman KM. Localization of eosinophil-derived neurotoxin and eosinophil cationic protein in neutrophilic leukocytes. J Leukoc Biol 1998;63:715-22.

39. Acharya KR, Ackerman SJ. Eosinophil granule proteins: form and function. J Biol Chem 2014;289:17406-15.

40. Gleich GJ, Loegering DA, Mann KG, Maldonado JE. Comparative properties of the Charcot-Leyden crystal protein and the major basic protein from human eosinophils. J Clin Invest 1976;57:635-40.

41. Lehrer RI, Szklarek D, Barton A, Ganz T, Hamann KJ, Gleich GJ. Antibacterial properties of eosinophil major basic protein and eosinophil cationic protein. J Immunol 1989;142:4428-34.

42. O'Donnell MC, Ackerman SJ, Gleich GJ, Thomas LL. Activation of basophil and mast cell histamine release by eosinophil granule major basic protein. J Exp Med 1983;157:1981-91.

43. Fujisawa D, Kashiwakura J, Kita H, Kikukawa Y, Fujitani Y, Sasaki-Sakamoto T, Kuroda K, Nunomura S, Hayama K, Terui T, Ra C, Okayama Y. Expression of Mas-related gene X2 on mast cells is upregulated in the skin of patients with severe chronic urticaria. J Allergy Clin Immunol 2014;134:622-33.e9.

44. Rohrbach MS, Wheatley CL, Silfman NR, Gleich GJ. Activation of platelets by eosinophil granule proteins. J Exp Med 1990;172:1271-4.

45. Kita H, Abu-Ghazaleh RI, Sur S, Gleich GJ. Eosinophil major basic protein induces degranulation and IL-8 production by human eosinophils. J Immunol 1995;154:4749-58.

46. Gleich GJ, Frigas E, Loegering DA, Wassom DL, Steinmuller D. Cytotoxic properties of the eosinophil major basic protein. J Immunol 1979;123:2925-7.

https://doi.org/10.5415/apallergy.2021.11.e30
47. Hastie AT, Loegering DA, Gleich GJ, Kueppers F. The effect of purified human eosinophil major basic protein on mammalian ciliary activity. Am Rev Respir Dis 1987;135:848-53.
PUBMED | CROSSREF

48. Pégorier S, Wagner LA, Gleich GJ, Pretolani M. Eosinophil-derived cationic proteins activate the synthesis of remodeling factors by airway epithelial cells. J Immunol 2006;177:4861-9.
PUBMED | CROSSREF

49. Jacoby DB, Gleich GI, Fryer AD. Human eosinophil major basic protein is an endogenous allosteric antagonist at the inhibitory muscarinic M2 receptor. J Clin Invest 1993;91:1314-8.
PUBMED | CROSSREF

50. Wilkerson EM, Johansson MW, Hebert AS, Westphall MS, Mathur SK, Jarjour NN, Schwantes EA, Mosher DF, Coon JJ. The peripheral blood eosinophil proteome. J Proteome Res 2016;15:1524-33.
PUBMED | CROSSREF

51. Sorrentino S, Tucker GK, Glitz DG. Purification and characterization of a ribonuclease from human liver. J Biol Chem 1988;263:16125-31.
PUBMED | CROSSREF

52. Yasuda T, Mizuta K, Sato W, Kishi K. Purification and characterization of a ribonuclease from human spleen. Immunological and enzymological comparison with nonsecretory ribonuclease from human urine. Eur J Biochem 1990;191:523-9.
PUBMED | CROSSREF

53. Mizuta K, Azwu S, Yasuda T, Kishi K. Purification and characterization of three ribonucleases from human kidney: comparison with urine ribonucleases. Arch Biochem Biophys 1990;281:144-51.
PUBMED | CROSSREF

54. Hamann KJ, Barker RL, Loegering DA, Gleich GJ. Comparative toxicity of purified human eosinophil granule proteins for newborn larvae of Trichinella spiralis. J Parasitol 1987;73:523-9.
PUBMED | CROSSREF

55. Gleich GJ, Loegering DA, Bell MP, Checkel JL, Ackerman SJ, McKean DJ. Biochemical and functional similarities between human eosinophil-derived neurotoxin and eosinophil cationic protein: homology with ribonuclease. Proc Natl Acad Sci U S A 1986;83:3146-50.
PUBMED | CROSSREF

56. Domachowske JB, Dyer KD, Bonville CA, Rosenberg HF. Recombinant human eosinophil-derived neurotoxin/RNase 2 functions as an effective antiviral agent against respiratory syncytial virus. J Infect Dis 1998;177:1458-64.
PUBMED | CROSSREF

57. Yang D, Chen Q, Su SB, Zhang P, Kurosaka K, Caspi RR, Michalek SM, Rosenberg HF, Zhang N, Oppenheim JJ. Eosinophil-derived neurotoxin acts as an alarmin to activate the TLR2-MyD88 signal pathway in dendritic cells and enhances Th2 immune responses. J Exp Med 2008;205:79-90.
PUBMED | CROSSREF

58. Rosenberg HF, Ackerman SJ, Tenen DG. Human eosinophil cationic protein. Molecular cloning of a cytotoxin and helminthotoxin with ribonuclease activity. J Exp Med 1989;170:163-76.
PUBMED | CROSSREF

59. Torrent M, Navarro S, Moussaoui M, Noguès MV, Boix E. Eosinophil cationic protein high-affinity binding to bacteria-wall lipopolysaccharides and peptidoglycans. Biochemistry 2008;47:3544-55.
PUBMED | CROSSREF

60. Pulido D, García-Mayoral MF, Moussaoui M, Velázquez D, Torrent M, Brux M, Boix E. Structural basis for endotoxin neutralization by the eosinophil cationic protein. FEBS J 2016;283:4176-91.
PUBMED | CROSSREF

61. Gullberg U, Widegren B, Arnason U, Egesten A, Olsson I. The cytotoxic eosinophil cationic protein (ECP) has ribonuclease activity. Biochim Biophys Res Commun 1986;139:1239-42.
PUBMED | CROSSREF

62. McLaren DJ, McKeveny J, Olsson I, Venges P, Kay AB. Morphological studies on the killing of schistosomula of Schistosoma mansoni by human eosinophil and neutrophil cationic proteins in vitro. Parasite Immunol 1981;3:359-73.
PUBMED | CROSSREF

63. Zheutlin LM, Ackerman SJ, Gleich GJ, Thomas LL. Stimulation of basophil and rat mast cell histamine release by eosinophil granule-derived cationic proteins. J Immunol 1984;133:2180-5.
PUBMED | CROSSREF

64. Venge P, Dahl R, Hållgren R. Enhancement of factor XII dependent reactions by eosinophil cationic protein. Thromb Res 1979;14:641-9.
PUBMED | CROSSREF
65. Dahl R, Venge P. Enhancement of urokinase-induced plasminogen activation by the cationic protein of human eosinophil granulocytes. Thromb Res 1979;14:599-608.

66. Torrent M, Pulido D, Nogué JS, Boix E. Exploring new biological functions of amyloids: bacteria cell agglutination mediated by host protein aggregation. PLoS Pathog 2012;8:e1003005.

67. Amber KT, Chernavskiy A, Agnoletti AF, Cozzani E, Grando SA. Mechanisms of pathogenic effects of eosinophil cationic protein and eosinophil-derived neurotoxin on human keratinocytes. Exp Dermatol 2018;27:1322-7.

68. Wang JG, Mahmud SA, Nguyen J, Slungaard A. Thiocyanate-dependent induction of endothelial cell adhesion molecule expression by phagocyte peroxidases: a novel HOSCN-specific oxidant mechanism to amplify inflammation. J Immunol 2006;177:8714-22.

69. Ten RM, Pease LR, McKean DJ, Bell MP, Gleich GJ. Molecular cloning of the human eosinophil peroxidase. Evidence for the existence of a peroxidase multigene family. J Exp Med 1989;169:1757-69.

70. Sullivan S, Salapow MA, Breen R, Broide DH. Eosinophil peroxidase differs from neutrophil myeloperoxidase in its ability to bind antineutrophil cytoplastics antibodies reactive with myeloperoxidase. Int Arch Allergy Immunol 1994;105:150-4.

71. Colon S, Yuan H, Liu Y, Meyer C, Gewin L, Bhave G. Peroxidasin and eosinophil peroxidase, but not myeloperoxidase, contribute to renal fibrosis in the murine unilateral ureteral obstruction model. Am J Physiol Renal Physiol 2019;316:F360-71.

72. Zabucchi G, Menegazzi R, Soranzo MR, Patriarca P. Uptake of human eosinophil peroxidase by human neutrophils. Am J Pathol 1986;124:510-8.

73. Dvorak AM, Klebanoff SJ, Henderson WR, Monahan RA, Pyne K, Galli SJ. Vesicular uptake of eosinophil peroxidase by guinea pig basophils and by cloned mouse mast cells and granule-containing lymphoid cells. Am J Pathol 1985;118:425-38.

74. Jong EC, Chi EY, Klebanoff SJ. Human neutrophil-mediated killing of schistosomula of Schistosoma mansoni: augmentation by schistosomal binding of eosinophil peroxidase. Am J Trop Med Hyg 1984;33:104-15.

75. Migler R, DeChatelet LR, Bass DA. Human eosinophil peroxidase: role in bactericidal activity. Blood 1978;51:445-56.

76. Jong EC, Klebanoff SJ. Eosinophil-mediated mammalian tumor cell cytotoxicity: role of the peroxidase system. J Immunol 1980;124:1949-53.

77. Wang JG, Mahmud SA, Thompson JA, Geng JG, Key NS, Slungaard A. The principal eosinophil peroxidase product, HOSCN, is a uniquely potent phagocyte oxidant inducer of endothelial cell tissue factor activity: a potential mechanism for thrombosis in eosinophil inflammatory states. Blood 2006;107:558-65.

78. Ramsey PG, Martin T, Chi E, Klebanoff SJ. Arming of mononuclear phagocytes by eosinophil peroxidase bound to Staphylococcus aureus. J Immunol 1982;128:415-20.

79. Dunican EM, Elicker BM, Gierada DS, Nagle SK, Schiebler ML, Newell JD, Raymond WW, Lachowicz-Srooggins ME, Di Maio S, Hoffman EA, Castro M, Faín SB, Jarjour NN, Israel E, Levy BD, Erzurum SC, Wenzel SE, Meyers DA, Bleecker ER, Phillips BR, Mauger DT, Gordon ED, Woodruff PG, Peters MC, Falty JV; National Heart Lung and Blood Institute (NHLBI) Severe Asthma Research Program (SARP). Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction. J Clin Invest 2018;128:907-1009.

80. Henderson WR, Chi EY, Klebanoff SJ. Eosinophil peroxidase-induced mast cell secretion. J Exp Med 1980;152:265-79.

81. Henderson WR, Jörg A, Klebanoff SJ. Eosinophil peroxidase-mediated inactivation of leukotrienes B4, C4, and D4. J Immunol 1982;128:2609-13.
82. Su J. A brief history of Charcot-Leyden Crystal protein/galectin-10 research. Molecules 2018;23:2931.

83. Melo RCN, Wang H, Silva TP, Imoto Y, Fujieda S, Fukuchi M, Miyabe Y, Hirokawa M, Ueki S, Weller PF. Galectin-10, the protein that forms Charcot-Leyden crystals, is not stored in granules but resides in the peripheral cytoplasm of human eosinophils. J Leukoc Biol 2020;108:139-49.

84. Ueki S, Tokunaga T, Melo RCN, Saito H, Honda K, Fukuchi M, Konno Y, Takeda M, Yamamoto Y, Hirokawa M, Fujieda S, Spencer LA, Weller PF. Charcot-Leyden crystal formation is closely associated with eosinophil extracellular trap cell death. Blood 2018;132:2183-7.

85. Persson EK, Verstraete K, Heyndrickx I, Gevaert E, Aegerter H, Percier JM, Deswarte K, Verschueren KHG, Dansercoer A, Gras D, Chanez P, Bachert C, Van Gorp H, De Haard H, Blanchetot C, Saunders M, Hammad H, Savvides SN, Lambrecht BN. Protein crystallization promotes type 2 immunity and is reversible by antibody treatment. Science 2019;364:eaaw4295.

86. Gevaert E, Delemarre T, De Volder J, Zhang N, Holtappels G, De Ruyck N, Persson E, Heyndrickx I, Verstraete K, Aegerter H, Nauwynck H, Savvides SN, Lambrecht BN, Bachert C. Charcot-Leyden crystals promote neutrophilic inflammation in patients with nasal polyps. J Allergy Clin Immunol 2020;145:427-30.e4.

87. Weller PF, Wang H, Melo RCN. The Charcot-Leyden crystal protein revisited-A lysopalmitoylphospholipase and more. J Leukoc Biol 2020;108:105-12.

88. Grozdanovic MM, Doyle CB, Liu L, Maybruck BT, Kwatia MA, Thiyaagara Nar N, Acharya KR, Ackerman SJ. Charcot-Leyden crystal protein/galectin-10 interacts with cationic ribonucleases and is required for eosinophil granulogenesis. J Allergy Clin Immunol 2020;146:377-89.e10.

89. Kaplan MJ, Radic M. Neutrophil extracellular traps: double-edged swords of innate immunity. J Immunol 2012;189:2689-95.

90. Hirsch JG. Bactericidal action of histone. J Exp Med 1958;108:925-44.

91. Barrero CA, Perez-Leal O, Aksoy M, Moncada C, Ji R, Lopez Y, Mallilankaraman K, Madesh M, Criner GJ, Kelsen SG, Merali S. Histone 3.3 participates in a self-sustaining cascade of apoptosis that contributes to the progression of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013;188:673-83.

92. Gilthorpe JD, Oozeer F, Nash J, Calvo M, Bennett DL, Luinsden A, Pini A. Extracellular histone H1 is neurotoxic and drives a pro-inflammatory response in microglia. F1000 Res 2013;2:148.

93. Huang H, Evankovich J, Yan W, Nace G, Zhang L, Ross M, Liao X, Billiar T, Xu J, Esmon CT, Tsung A. Endogenous histones function as alarmins in sterile inflammatory liver injury through Toll-like receptor 9 in mice. Hepatology 2011;54:999-1008.

94. Kawano H, Ito T, Yamada S, Hashiguchi T, Maruyama I, Hisatomi T, Nakamura M, Sakamoto T. Toxic effects of extracellular histones and their neutralization by vitreous in retinal detachment. Lab Invest 2014;94:569-85.

95. Semeraro F, Ammollo CT, Morrissey JH, Dale GL, Friese P, Esmon NL, Esmon CT. Extracellular histones promote thrombin generation through platelet-dependent mechanisms: involvement of platelet TLR2 and TLR4. Blood 2011;118:1952-61.

96. Fuchs TA, Bhandari AA, Wagner DD. Histones induce rapid and profound thrombocytopenia in mice. Blood 2011;118:3708-14.
99. Ammollo CT, Semeraro F, Xu J, Esmon NL, Esmon CT. Extracellular histones increase plasma thrombin generation by impairing thrombomodulin-dependent protein C activation. J Thromb Haemost 2011;9:1795-803.
PUBMED | CROSSREF

100. Carestia A, Rivadeneyra L, Romaniuk MA, Fondevila C, Negrotto S, Schattner M. Functional responses and molecular mechanisms involved in histone-mediated platelet activation. Thromb Haemost 2013;110:1035-45.
PUBMED | CROSSREF

101. Lam FW, Cruz MA, Leung HC, Parikh KS, Smith CW, Rumbaut RE. Histone induced platelet aggregation is inhibited by normal albumin. Thromb Res 2013;132:69-76.
PUBMED | CROSSREF

102. Villanueva E, Yalavarthi S, Berthier CC, Hodgin JB, Punaro M, Baisch J, Guiducci C, Coffman RL, Barrat FJ, Banchereau J, Pascual V. Neutrophil extracellular traps induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. J Immunol 2011;187:538-52.
PUBMED | CROSSREF

103. Gupta AK, Joshi MB, Philippova M, Erne P, Hasler P, Hahn S, Resink TJ. Activated endothelial cells induce neutrophil extracellular traps and are susceptible to NETosis-mediated cell death. FEBS Lett 2010;584:3193-7.
PUBMED | CROSSREF

104. Garcia-Romo GS, Caielli S, Vega B, Connolly J, Allantaz F, Xu Z, Punaro M, Baisch J, Guiducci C, Coffman RL, Barrat FJ, Pascual V. Neutrophil extracellular traps are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci Transl Med 2011;3:73ra20.
PUBMED | CROSSREF

105. Lee E, Robertson T, Smith J, Kilfeather S. Leukotriene receptor antagonists and synthesis inhibitors reverse survival in eosinophils of asthmatic individuals. Am J Respir Crit Care Med 2000;161:1881-6.
PUBMED | CROSSREF

106. Saito K, Nagata M, Kikuchi I, Sakamoto Y. Leukotriene D4 and eosinophil transendothelial migration, superoxide generation, and degranulation via beta2 integrin. Ann Allergy Asthma Immunol 2004;93:594-600.
PUBMED | CROSSREF

107. Kita H, Ohnishi T, Okubo Y, Weiler D, Abrams JS, Gleich GJ. Granulocyte/macrophage colony-stimulating factor and interleukin 3 release from human peripheral blood eosinophils and neutrophils. J Exp Med 1991;174:745-8.
PUBMED | CROSSREF

108. Moqbel R, Hamid Q, Ying S, Barkans J, Hartnell A, Tsiropoulos A, Wardlaw AJ, Kay AB. Expression of mRNA and immunoreactivity for the granulocyte/macrophage colony-stimulating factor in activated human eosinophils. J Exp Med 1991;174:749-52.
PUBMED | CROSSREF
115. Anwar AR, Moqbel R, Walsh GM, Kay AB, Wardlaw AJ. Adhesion to fibronectin prolongs eosinophil survival. J Exp Med 1993;177:839-43.

116. Ohno I, Nitto Y, Yamauchi K, Hoshi H, Honma M, Woolley K, O'Byrne P, Tamura G, Jordana M, Shirato K. Transforming growth factor beta 1 (TGF beta 1) gene expression by eosinophils in asthmatic airway inflammation. Am J Respir Cell Mol Biol 1996;15:404-9.

117. Minshall EM, Leung DYM, Martin RJ, Song YL, Cameron L, Ernst P, Hamid Q. Eosinophil-associated TGF-β1 mRNA expression and airways fibrosis in bronchial asthma. Am J Respir Cell Mol Biol 1997;17:326-33.

118. Wong DT, Elovic A, Matossian K, Nagura N, McBride J, Chou MY, Gordon JR, Rand TH, Galli SJ, Weller PF. Eosinophils from patients with blood eosinophilia express transforming growth factor beta 1. Blood 1991;78:2702-7.

119. Bochner BS, Klunk DA, Sterbinsky SA, Coffman RL, Schleimer RP. IL-13 selectively induces vascular cell adhesion molecule-1 expression in human endothelial cells. J Immunol 1995;154:799-803.

120. Yamashita N, Tashimo H, Ishida H, Kaneko F, Nakano J, Kato H, Hirai K, Horiuichi T, Ohta K. Attenuation of airway hyperresponsiveness in a murine asthma model by neutralization of granulocyte-macrophage colony-stimulating factor (GM-CSF). Cell Immunol 2002;219:92-7.

121. Willart MA, Deswarte K, Pouliot P, Braun H, Beyaert R, Lambrecht BN, Hammad H. Interleukin-1α controls allergic sensitization to inhaled house dust mite via the epithelial release of GM-CSF and IL-33. J Exp Med 2012;209:1505-17.

122. Akuthota P, Weller PF. Eosinophilic pneumonias. Clin Microbiol Rev 2012;25:649-60.

123. Sakao S. Acute eosinophilic pneumonia and heated tobacco products. Intern Med 2020;59:2807.

124. De Giacomi F, Vassallo R, Yi ES, Ryu JH. Acute eosinophilic pneumonia causes, diagnosis, and management. Am J Respir Crit Care Med 2018;197:728-36.

125. Kobayashi Y, Ueki S, Mahemuti G, Chiba T, Oyamada H, Kanda A, Kayaba H, Chihara J. Physiological levels of 15-deoxy-Delta12,14-prostaglandin J2 prime eotaxin-induced chemotaxis on human eosinophils through peroxisome proliferator-activated receptor-gamma ligation. J Immunol 2005;175:5744-50.

126. Jhun BW, Kim SJ, Kim K, Lee JE, Hong DJ. Clinical implications of correlation between peripheral eosinophil count and serum levels of IL-5 and tryptase in acute eosinophilic pneumonia. Respir Med 2014;108:1655-62.

127. Durham SR, Kay AB. Eosinophils, bronchial hyperreactivity and late-phase asthmatic reactions. Clin Allergy 1985;15:411-8.

128. Dormans SC, Sehmi R, Gauvreau GM, Watson RM, Foley R, Jones GL, Denburg JA, Inman MD, O'Byrne PM. Kinetics of bone marrow eosinophilopoiesis and associated cytokines after allergen inhalation. Am J Respir Crit Care Med 2004;169:565-72.

129. Farahi N, Louisios C, Peters AM, Condiliffe AM, Chilvers ER. Use of technetium-99m-labeled eosinophils to detect active eosinophilic inflammation in humans. Am J Respir Crit Care Med 2013;188:880-2.

130. Farahi N, Singh NR, Heard S, Louisios C, Summers C, Solanki CK, Solanki K, Balan KK, Ruparelia P, Peters AM, Condiliffe AM, Chilvers ER. Use of 111-In-Indium-labeled autologous eosinophils to establish the in vivo kinetics of human eosinophils in healthy subjects. Blood 2012;120:4068-71.

131. Pattnode ML, Bando IK, Krummel MF, Locksley RM, Rosen SD. Leukotriene B4 amplifies eosinophil accumulation in response to nematodes. J Exp Med 2014;211:1281-8.
132. Kobayashi Y, Konno Y, Kanda A, Yamada Y, Yasuba H, Sakata Y, Fukushima M, Tomoda K, Iwai H, Ueki S. Critical role of CCL4 in eosinophil recruitment into the airway. Clin Exp Allergy 2019;49:853-60.

133. Suzuki Y, Suda T. Eosinophilic pneumonia: a review of the previous literature, causes, diagnosis, and management. Allergol Int 2019;68:413-9.

134. Philit E, Etienne-Mastroianni B, Parrot A, Guérin C, Robert D, Cordier JF. Idiopathic acute eosinophilic pneumonia: a study of 22 patients. Am J Respir Crit Care Med 2002;166:1235-9.

135. Bentley AM, Hamid Q, Robinson DS, Schotman E, Meng Q, Assoufi B, Kay AB, Durham SR. Prednisolone treatment in asthma. Reduction in the numbers of eosinophils, T cells, tryptase-only positive mast cells, and modulation of IL-4, IL-5, and interferon-gamma cytokine gene expression within the bronchial mucosa. Am J Respir Crit Care Med 1996;153:551-6.

136. Drulilhe A, Létuve S, Pretolani M. Glucocorticoid-induced apoptosis in human eosinophils: mechanisms of action. Apoptosis 2003;8:481-95.

137. Felton JM, Lucas CD, Rossi AG, Dransfield I. Eosinophils in the lung - modulating apoptosis and effectorcytosis in airway inflammation. Front Immunol 2014;5:302.

138. Stern M, Meagher L, Savill J, Haslett C. Apoptosis in human eosinophils. Programmed cell death in the eosinophil leads to phagocytosis by macrophages and is modulated by IL-5. J Immunol 1992;148:3543-9.

139. Izumiya Y, Okuda Y, Ueki S, Takeda M, Sato K, Nakayama K. Unusual morphologies of blood eosinophils in GM-CSF-producing lung cancer. QJM 2021;114:42-4.

140. Faiz S, Giovannelli J, Podevin C, Jachiet M, Bouaziz JD, Reguiai Z, Gossema A, Lasek A, Ferrier le Boudec MC, Du Thanh A, Raison-Peyron N, Tetart F, Duval-Moderste AB, Misery L, Aubin F, Dompmartin A, Morice C, Droitcourt C, Soria A, Renaud JP, Delaunay J, Mahé E, Richard MA, Schoeffler A, Lacour JP, Bego N, Walter-Lepage A, Dillès AS, Rappelle-Duruy S, Baret S, Bellon N, Bénèton N, Valois A, Barbot S, Sénéchal J, Staumont-Salle D; Groupe de Recherche sur l’Eczéma aTopique (GREAT). France. Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort. J Am Acad Dermatol 2019;81:143-51.

141. Gotlib J. World Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management. Am J Hematol 2017;92:1243-59.

142. Prakash Babu S, Chen YK, Bonne-Annee S, Yang J, Maric I, Myers TG, Nutman TB, Klion AD. Dysregulation of interleukin 5 expression in familial eosinophilia. Allergy 2017;72:1338-45.

143. Schwartz JT, Fulkerson PC. An approach to the evaluation of persistent hypereosinophilia in pediatric patients. Front Immunol 2018;9:1944.

144. Frigas E, Gleich GI. The eosinophil and the pathophysiology of asthma. J Allergy Clin Immunol 1986;77:527-37.
149. Kephart GM, Gleich GJ, Connor DH, Gibson DW, Ackerman SJ. Deposition of eosinophil granule major basic protein onto microfilariae of Onchocerca volvulus in the skin of patients treated with diethylcarbamazine. Lab Invest 1984;50:51-61.

150. Peters MS, Schroeter AL, Kephart GM, Gleich GJ. Localization of eosinophil granule major basic protein in chronic urticaria. J Invest Dermatol 1983;81:39-43.

151. Cheng JF, Ott NL, Peterson EA, George TJ, Hukee MJ, Gleich GJ, Leiferman KM. Dermal eosinophils in atopic dermatitis undergo cytolytic degeneration. J Allergy Clin Immunol 1997;99:683-92.

152. Wright BL, Leiferman KM, Gleich GJ. Eosinophil granule protein localization in eosinophil endomyocardial disease. N Engl J Med 2011;365:187-8.

153. Noguchi H, Kephart GM, Colby TV, Gleich GJ. Tissue eosinophilia and eosinophil degranulation in syndromes associated with fibrosis. Am J Pathol 1992;140:521-8.

154. Chung HL, Kwong JB, Kwon YD, Park MH, Shin WJ, Park JB. Deposition of eosinophil-granule major basic protein and expression of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in the mucosa of the small intestine in infants with cow’s milk-sensitive enteropathy. J Allergy Clin Immunol 1999;103:1195-201.

155. Kuwahara T, Kobayashi Y, Yun Y, Kanda A, Asako M, Ueki S, Iwai H. Eosinophilic cholecystitis occurred in a patient with refractory eosinophilic airway inflammation: a case report. Allergy Rhinol (Providence) 2019;10:215265719869607.

156. Hamada S, Ueki S, Miyabe Y, Tsukino M, Hirai T. Focal eosinophilic myositis with Charcot-Leyden crystal formation. Allergol Int 2020;69:633-5.

157. Kawamura Y, Ikeda R, Hori T, Sasaki T, Miyabe Y, Fukuchi M, Sakamoto K, Ohta N, Kawase T, Katori Y, Ueki S. Sialodochitis fibrinosa: Salivary duct obstruction by eosinophil extracellular traps? Oral Dis 2020;26:1459-63.

158. Nogawa H, Suzuki H, Kawabata Y, Ota T, Yuki Y, Katagiri Y, Hino T, Yanagawa N, Ueki S. An unusual case of eosinophilic lung disease with multiple cyst formation. Respi Med Case Rep 2020;31:101300.

159. Takeda M, Ueki S, Yamamoto Y, Nara M, Fukuchi M, Nakayama K, Omori Y, Takahashi N, Hirokawa M. Hypereosinophilic syndrome with abundant Charcot-Leyden crystals in spleen and lymph nodes. Asia Pac Allergy 2020;10:e24.

160. Fukuchi M, Miyabe Y, Furutani C, Saga T, Moritoki Y, Yamada T, Weller PF, Ueki S. How to detect eosinophil ETosis (EETosis) and extracellular traps. Allergol Int 2021;70:19-29.

161. Walters MJ, Paul-Clark MJ, McMaster SK, Ito K, Adcock IM, Mitchell JA. Cigarette smoke activates human monocytes by an oxidant-AP-1 signaling pathway: implications for steroid resistance. Mol Pharmacol 2005;68:1343-53.

162. Butterworth AE, Vadis MA, Wassom DL, Dessein A, Hogan M, Sherry B, Gleich GJ, David JR. Interactions between human eosinophils and schistosomula of schistosoma mansoni. II. The mechanism of irreversible eosinophil adherence. J Exp Med 1979;150:1456-71.

163. Gleich GJ, Adolphson CR, Leiferman KM. The biology of the eosinophilic leukocyte. Annu Rev Med 1993;44:85-101.

164. Zheutlin LM, Ackerman SJ, Gleich GJ, Thomas LL. Donor sensitivity to basophil activation by eosinophil granule major basic protein. Int Arch Allergy Appl Immunol 1985;77:216-7.

165. Soragni A, Yousefi S, Stoeckle C, Sorigga AB, Sawaya MR, Kozowski E, Schmid I, Radonjic-Hoesli S, Bouter S, Williams GI, Messerschmidt M, Seibert MM, Caccio D, Zatsepina NA, Burghammer M, Riekel C, Colletier JP, Riek R, Eisenberg DS, Simon HU. Toxicity of eosinophil MBP is repressed by intracellular crystallization and promoted by extracellular aggregation. Mol Cell 2015;57:1011-21.
166. Slifman NR, Loegering DA, McKean DJ, Gleich GJ. Ribonuclease activity associated with human eosinophil-derived neurotoxin and eosinophil cationic protein. J Immunol 1986;137:2913-7.

PUBMED

167. Fredens K, Dahl R, Venge P. The Gordon phenomenon induced by the eosinophil cationic protein and eosinophil protein X. J Allergy Clin Immunol 1982;70:364-6.

PUBMED | CROSSREF

168. Rosenberg HF, Dyer KD. Eosinophil cationic protein and eosinophil-derived neurotoxin. Evolution of novel function in a primate ribonuclease gene family. J Biol Chem 1995;270:30234.

PUBMED | CROSSREF

169. Kubach J, Lutter P, Bopp T, Stoll S, Becker C, Huter E, Richter C, Weingarten P, Warger T, Knop J, Müllner S, Wijdenes J, Schild H, Schmitz E, Jonuleit H. Human CD4+CD25+ regulatory T cells: proteome analysis identifies galectin-10 as a novel marker essential for their anergy and suppressive function. Blood 2007;110:1550-8.

PUBMED | CROSSREF

170. Mishra B, von der Ohe M, Schulze C, Bian S, Makhina T, Loers G, Kleene R, Schachner M. Functional role of the interaction between polysialic acid and extracellular histone H1. J Neurosci 2010;30:12400-43.

PUBMED | CROSSREF

171. Brix K, Summa W, Lottspeich F, Herzog V. Extracellularly occurring histone H1 mediates the binding of thyroglobulin to the cell surface of mouse macrophages. J Clin Invest 1998;102:283-93.

PUBMED | CROSSREF

172. Xu J, Zhang X, Pelayo R, Monestier M, Ammollo CT, Semeraro F, Taylor FB, Esmon NL, Lupu F, Esmon CT. Extracellular histones are major mediators of death in sepsis. Nat Med 2009;15:1318-21.

PUBMED | CROSSREF

173. Bosmann M, Grailer JJ, Ruemmler R, Russkamp NF, Zetoune FS, Sarma JV, Standiford TJ, Ward PA. Extracellular histones are essential effectors of C5aR- and C5L2-mediated tissue damage and inflammation in acute lung injury. FASEB J 2013;27:5010-21.

PUBMED | CROSSREF

174. Allam R, Scherbaum CR, Darisipudi MN, Mulay SR, Hägele H, Lichtneker J, Hagemann IH, Rupanagudi KV, Ryu M, Schwarzenberger C, Hohenstein B, Hugo C, Uhl B, Reichel CA, Krombach F, Monestier M, Liapis H, Moreth K, Schaefer L, Anders HJ. Histones from dying renal cells aggravate kidney injury via TLR2 and TLR4. J Am Soc Nephrol 2012;23:1375-88.

PUBMED | CROSSREF

175. Hakkim A, Fürnrohr BG, Amann K, Laube B, Abed UA, Brinkmann V, Herrmann M, Voll RE, Zychlinsky A. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc Natl Acad Sci U S A 2010;107:9813-8.

PUBMED | CROSSREF

176. Fuchs TA, Brill A, Duerschmied D, Schatzberg D, Monestier M, Myers DD Jr, Wrobleski SK, Wakefield TW, Hartwig IH, Wagner DD. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci U S A 2010;107:15880-5.

PUBMED | CROSSREF